Mylan Stock Buy Or Sell -

~$14.67, indicating a slight forecasted downside of roughly -1% . Target Range: High of $18.00 and a low of $10.00 . Investment Case: Buy vs. Sell Buy Case (Bullish) Sell/Hold Case (Bearish)

Management expects roughly 2% total revenue growth and strong free cash flow exceeding $2.5 billion .

AI responses may include mistakes. For financial advice, consult a professional. Learn more mylan stock buy or sell

The company is focusing on higher-margin generic launches and its innovative portfolio, including late-stage assets expected to complete enrollment in 2026. Market Cap: ~$17.25 billion as of April 2026.

Mylan (formerly NASDAQ: MYL) no longer exists as an independent stock. In November 2020, Mylan merged with Pfizer’s Upjohn business to form a new company called (NASDAQ: VTRS ). Sell Buy Case (Bullish) Sell/Hold Case (Bearish) Management

To evaluate whether to "buy or sell," you must look at performance and analyst sentiment as of April 2026. Viatris (VTRS) Analyst Ratings & Price Targets (April 2026)

Recent FDA warnings and import alerts regarding manufacturing facilities in India (Indore and Nashik) continue to impact EBITDA estimates. Learn more The company is focusing on higher-margin

Discounted Cash Flow (DCF) models suggest the stock is significantly undervalued, with some estimates placing "fair value" as high as $56.03 .